



July 22, 2010

Corporate Facts

& Figures

Cytos Biotechnology at a Glance

- Cytos Biotechnology is a public Swiss biotechnology company that focuses on the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™.
- Immunodrugs™ are therapeutic vaccines intended for use in the treatment and prevention of common chronic diseases that afflict millions of people worldwide.
- Founded in 1995, Cytos Biotechnology currently has 76 full-time employees and is headquartered in Schlieren (Zurich), Switzerland.
- Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange:
 - registered shares – SIX:CYTN
 - convertible bond due in 2012 – SIX:CYT07

Recent News

- July 2010 – A*STAR & Cytos Biotechnology establish influenza vaccine collaboration.
- May 2010 – Cytos Biotechnology Ltd and Intercell AG close the sale of a platform technology for EUR 15 million.
- May 2010 – Placebo-controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma.
- May 2010 – Cytos Biotechnology sells platform technology for the identification of monoclonal antibodies to Intercell.
- May 2010 – Harry Welten succeeds Jakob Schlapbach as CFO, Jakob Schlapbach elected to the Board of Directors.
- March 2010 – Partner Novartis starts a further placebo-controlled phase II study with the vaccine candidate CAD106 in 120 Alzheimer's disease patients.

Business Strategy

- Chronic disease treatment and prevention requires early intervention and long-term patient compliance to respective therapies if individual well-being is to be maintained. Cytos Biotechnology's Immunodrugs™ represent a new therapeutic modality that aims to offer therapeutic benefit and convenient dosing schedules to individual patients as well as economic benefit to payers of treatment and society in general.
- Cytos Biotechnology generally selects disease indications with well understood disease mechanisms and therapeutic pathways where Immunodrugs™ should provide for an attractive treatment solution.
- To maximize the commercial potential of its Immunodrug™ platform, Cytos Biotechnology intends to follow different avenues:
 - selectively partner Immunodrug™ projects addressing mass markets after clinical proof-of-concept (e.g. in phase II trials) with leading pharmaceutical companies;
 - provide pharmaceutical companies with access to the Immunodrug™ technology in well defined, target-specific licensing arrangements outside the scope of Cytos Biotechnology's own R&D programs; and,
 - benefit from potential cross-sector opportunities by applying Immunodrugs™ in human and animal health.

Product Pipeline (July 2010)

		Preclinical	Phase I	Phase II	Phase IIb
Respiratory	NIC002 for smoking cessation	<i>partnered with Novartis</i>			
	CYT003-QbG10 for allergic rhinoconjunctivitis				
	CYT003-QbG10 for allergic asthma				
Cardiovascular	CYT006-AngQb for hypertension				
	IL1aQb for atherosclerosis				
Nervous system	CAD106 for Alzheimer's disease	<i>partnered with Novartis</i>			
Oncology	CYT004-MelQbG10 for malignant melanoma				
Metabolic	CYT013-IL1bQb for type II diabetes				
Inflammation/ autoimmunity	TNFQb for RA*, psoriasis, Crohn's disease				
	IL17Qb for multiple sclerosis, psoriasis				

* RA = rheumatoid arthritis

Product Pipeline

Cytos Biotechnology has built a diversified pipeline of Immunodrug™ candidates targeting important chronic disease indications. Six product candidates for smoking cessation, allergy and asthma, Alzheimer's disease, hypertension, type II diabetes and malignant melanoma are currently in clinical development. The Immunodrug™ programs for smoking cessation and Alzheimer's disease are both partnered with Novartis. In addition, Immunodrug™ collaborations are ongoing with Pfizer in undisclosed human and animal health applications.

Partnerships

- Cytos Biotechnology's innovative technologies and product candidates are partnered with top-tier pharmaceutical companies. The main partners are Novartis, Pfizer, Pfizer Animal Health and Solidago.
- A worldwide scientific network with prestigious academic research institutions gives Cytos Biotechnology prime access to cutting-edge science, disease-specific know-how and additional specimens and research materials.

Contact

Cytos Biotechnology Ltd
Wagistrasse 25
CH-8952 Schlieren (Zurich)
Switzerland
Phone +41 44 733 47 47
Fax +41 44 733 47 40
info@cytos.com
www.cytos.com

Financial Overview

in CHF million	Q2 2010	full year 2009
Revenue	21.2	9.1
Net operating costs	(7.5)	(36.3)
Net income/(loss)	15.0	(24.8)
in CHF million	June 30, 2010	December 31, 2009
Cash, cash equivalents, financial assets & trade receivables	56.6	60.5
Nominal value of the convertible bonds held by Cytos Biotechnology Ltd	41.1	57.1
Number of full time employees	76	85

The full financial statements can be found on www.cytos.com

Disclaimer: This fact sheet has the sole purpose to provide, in a simplified way, an overview of Cytos Biotechnology and its activities. Cytos Biotechnology can offer neither assurance that this overview is complete nor that its technology and product candidates will be successful. This fact sheet does not constitute or form part of an offer to subscribe or purchase any securities of Cytos Biotechnology Ltd. Any person considering the purchase of or subscription to securities in Cytos Biotechnology Ltd shall inform himself independently from other sources before taking any investment decision. Forward-looking statements represent the judgment and expectation of Cytos Biotechnology's management concerning the development of Cytos Biotechnology. However, a number of risks and uncertainties could cause actual developments and results to differ materially from Cytos Biotechnology's expectation.